Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SP0237
- Development stage
- Discontinued
- Lead developer
- Sanofi
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular
01
Overview
SP0237 is an experimental, next-generation mRNA-based influenza vaccine developed by Sanofi. Unlike first-generation mRNA flu vaccines that primarily target the hemagglutinin (HA) protein, SP0237 is designed to encode both HA and neuraminidase (NA) antigens. This dual-antigen approach is intended to elicit a broader and more durable immune response, potentially improving protection against a wider range of influenza strains and addressing the reduced efficacy against influenza B strains observed with HA-only mRNA platforms. The vaccine utilizes lipid nanoparticle (LNP) technology for delivery. SP0237 entered Phase 1/2 clinical trials in 2024 as a successor to Sanofi's earlier candidate, SP0273. However, in early 2026, Sanofi announced the deprioritization of its seasonal mRNA flu program, including SP0237, as part of a strategic shift to focus on other vaccine priorities, such as combination respiratory vaccines.
- Other names
- next-generation mRNA influenza vaccineneuraminidase-encoding mRNA influenza vaccineenhanced mRNA influenza vaccine
02
Targets
NeuraminidaseHA (Hemagglutinin)
Beyond the preview
Go deeper on SP0237.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SP0237.